Indication
Neck Cancer
2 clinical trials
3 products
3 drugs
Clinical trial
A Phase 1b, Open-Label, Single-Arm Dose-Expansion Study of IK-175, an Oral Aryl Hydrocarbon Receptor Inhibitor, in Combination With Nivolumab in Patients With Primary PD-1 Inhibitor Resistant Metastatic or Locally Incurable, Recurrent HNSCCStatus: Withdrawn, Estimated PCD: 2023-04-01
Product
IK-175 + NivolumabClinical trial
A Pilot Study of Neoadjuvant Cemiplimab With Platinum-Doublet Chemotherapy, and Cetuximab in Patients With Resectable, Locally Advanced Head and Neck Squamous Cell CarcinomaStatus: Recruiting, Estimated PCD: 2026-06-20
Drug
CisplatinDrug
AN0025Drug
DocetaxelProduct
CetuximabProduct
Cemiplimab